Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies

被引：2
|
作者：
Comeau, Michael R.
Mitchell, Danielle
Gottschalk, Rebecca
Misher, Lynda
Daugherty, Mollie
Parr, Lara
Pavlik, Peter
Woodruff, Brian
Fang, Hang
Aguilar, Megan
Bannink, Jeannette
Johnson, Starrla
Li, Gary
Miller, Robert E.
Bader, Robert
Zhang, Nicole
Sewell, Toddy
Dasovich, Maria
Hoyos, Gabriela H.
Blankenship, John W.
McMahan, Catherine
Bienvenue, David
Gross, Jane A.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Immunotherapy with Long-Lived Anti-CD123 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD1 23+Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia
    Chu, Seung Y.
    Pong, Erik
    Chen, Hsing
    Phung, Sheryl
    Chan, Emily W.
    Endo, Nancy A.
    Rashid, Rumana
    Bonzon, Christine
    Leung, Irene W. L.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Bernett, Matthew J.
    Szymkowski, David E.
    Desjarlais, John R.
    BLOOD, 2014, 124 (21)
  • [32] The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
    van Diest, Eline
    Nicolasen, Mara J. T.
    Kramer, Lovro
    Zheng, Jiali
    Hernandez-Lopez, Patricia
    Beringer, Dennis X.
    Kuball, Jurgen
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [33] T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    Bernd Schlereth
    Cornelia Quadt
    Torsten Dreier
    Peter Kufer
    Grit Lorenczewski
    Nadja Prang
    Christian Brandl
    Sandra Lippold
    Kathy Cobb
    Kathleen Brasky
    Eugen Leo
    Ralf Bargou
    Krishna Murthy
    Patrick A. Baeuerle
    Cancer Immunology, Immunotherapy, 2006, 55 : 503 - 514
  • [34] T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    Schlereth, B
    Quadt, C
    Dreier, T
    Kufer, P
    Lorenczewski, G
    Prang, N
    Brandl, C
    Lippold, S
    Cobb, K
    Brasky, K
    Leo, E
    Bargou, R
    Murthy, K
    Baeuerle, PA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (05) : 503 - 514
  • [35] Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody
    Xiong, DS
    Xu, YF
    Liu, HZ
    Peng, H
    Shao, XF
    Lai, ZZ
    Fan, DM
    Yang, M
    Han, JL
    Xie, Y
    Yang, CZ
    Zhu, ZQ
    CANCER LETTERS, 2002, 177 (01) : 29 - 39
  • [36] PROMOTION OF NATURAL-KILLER-CELL GROWTH IN-VITRO BY BISPECIFIC (ANTI-CD3 X ANTI-CD16) ANTIBODIES
    MALYGIN, AM
    SOMERSALO, K
    TIMONEN, T
    IMMUNOLOGY, 1994, 81 (01) : 92 - 95
  • [37] T-CELL RESPONSE TO ANTI-CD3 ANTIBODY IN DOWNS-SYNDROME
    BERTOTTO, A
    ARCANGELI, C
    CRUPI, S
    MARINELLI, I
    GERLI, R
    VACCARO, R
    ARCHIVES OF DISEASE IN CHILDHOOD, 1987, 62 (11) : 1148 - 1151
  • [38] Preparation and characterization for bispecific antibodies of anti-CD3 X anti-idiotype to B cell lymphocytic leukemia
    Shen Guanxin
    Zhang Yue
    Zhu Huifen
    Yang Jing
    Wang Xiaolin
    Current Medical Science, 1999, 19 (3) : 166 - 169
  • [39] Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
    Subklewe, Marion
    Magno, Giulia
    Gebhardt, Christina
    Buecklein, Veit
    Szelinski, Franziska
    Arevalo, Hector Julian Rincon
    Haenel, Gerulf
    Doerner, Thomas
    Zugmaier, Gerhard
    von Bergwelt-Baildon, Michael
    Skapenko, Alla
    Schulze-Koops, Hendrik
    EUROPEAN JOURNAL OF CANCER, 2024, 204
  • [40] Response to "In vivo secretion of anti-CD3 x anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement"
    Iwahori, Kota
    Song, Xiao-Tong
    Gottschalk, Stephen
    MOLECULAR THERAPY, 2015, 23 (04) : 613 - 613
12345